Biotron : Chairman's Address and Presentation to AGM

For personal use only

	Level 2, 66 Hunter Street
	Sydney NSW 2000
	Tel: [phone]
	Fax: [phone]
	E-mail: [e-mail]
	Website: www.biotron.com.au
23 November 2021
The Manager Companies
ASX Limited
20 Bridge Street
SYDNEY NSW 2000	(16 pages by email)
Dear Madam,

PRESENTATION TO ANNUAL GENERAL MEETING

I attach a Chairman's Address and a PowerPoint presentation to be delivered at today's Annual General Meeting which is convened to be held at 11.00 am.

This announcement has been approved by the Company's Managing Director.

Yours faithfully

Peter J. Nightingale

Company Secretary

pjn11035

For personal use only

Level 2, 66 Hunter Street

Sydney NSW 2000

Tel: [phone]

Fax: [phone]

E-mail: [e-mail]

Website: www.biotron.com.au

23 November 2021

CHAIRMAN'S ADDRESS TO THE AGM

My Fellow Shareholders

Due to the health and safety impact of COVID-19, and the continuing developments around government mandated restrictions, this meeting is again being conducted in virtual format. We hope, sincerely, next year allows a return to a normal AGM.

Despite historical headwinds, this has been a particularly significant year for Biotron.

Significant for a breakthrough in the clinical trial design which greatly benefits our primary program targeting the eradication of HIV.

Significant for the substantial steps achieved in identifying a groundbreaking means of combatting Hepatitis B and notably significant because of advances in our particularly exciting drug development program aimed at delivering a therapeutic solution for COVID-19.

Each of these topics will be covered in the Managing Director's report, however, it should be clearly noted that, by itself, any one of these programs, is a company making program. In combination, our programs demonstrate the significance and considerable importance of our overriding antiviral platform. Focus on individual programs often overlooks the depth and underlying strength of our Company.

For any person engaged in the antiviral space, worldwide, the past two years have presented challenges not experienced in our lifetime. Biotron's small, but dedicated, team of staff and consultants have, against the odds, delivered all that was expected of them and much more.

This in no way diminishes shareholder frustration regarding the commercialisation of our products. As shareholders ourselves, your directors clearly understand your concerns.

To date, Biotron has successfully completed nine human clinical trials. We are currently engaged in two more. That, in itself, speaks volumes for the determination demonstrated during these trying times. We do not undertake such major - and costly - steps lightly. The trials are tightly focused and based in no small way on feedback and input from likely partners. These trials are necessary scientifically and value enhancing commercially.

For personal use only

Drug development, as we all well know, is a slow and complicated, process. Regulatory processes quite rightly ensure there are no shortcuts. There are three basic requirements: Good science, clear imminent medical need and quality data. Biotron ticks these boxes. Our programs are carefully planned, professionally managed and absolutely necessary. We develop innovative solutions for people with serious and life-threatening conditions. We remain confident of a positive outcome for our COVID-19 program and, in that event, it will have been down to the practical, sensible and clear steps which allowed the Company to respond as quickly as possible to a health threat of such shattering proportions.

Your directors believe, unquestionably, that this Company is on the right path to deliver tangible results to the benefit of patients suffering these terrible ailments and, importantly for this meeting, our shareholders.

Michael J. Hoy

Chairman

ersonal use only

BIOTRON LIMITED (ASX:BIT)

AGM

23 November 2021

Forward Looking Statements

ersonal use only

This presentation may contain forward‐looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of

the plans and objectives of its management. These statements are statements that are not historical

facts. Words such as "should", "expects", "anticipates", "estimates", "believes" or similar expressions, as they relate to Biotron Limited, are intended to identify forward‐looking statements. By their

nature, forward‐looking statements involve risk and uncertainty because they reflect Biotron's

current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any

changes in such assumptions or expectations could cause actual results to differ materially from

current expectations.